- Home
- ZION vs HALO Comparison
ZION vs HALO Comparison
Compare ZION & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZION | HALO |
|---|---|---|
| Founded | 1873 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 7.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ZION | HALO |
|---|---|---|
| Price | $58.62 | $67.39 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 19 | 12 |
| Target Price | $60.74 | ★ $73.33 |
| AVG Volume (30 Days) | 1.5M | ★ 2.2M |
| Earning Date | 01-20-2026 | 02-17-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | 27.47 | ★ 56.68 |
| EPS | ★ 5.59 | 4.74 |
| Revenue | ★ $3,207,000,000.00 | $1,242,852,000.00 |
| Revenue This Year | $12.03 | $34.83 |
| Revenue Next Year | $4.35 | $24.84 |
| P/E Ratio | ★ $10.50 | $14.29 |
| Revenue Growth | 6.54 | ★ 31.19 |
| 52 Week Low | $39.32 | $47.50 |
| 52 Week High | $60.77 | $79.50 |
Technical Indicators
Market Signals| Indicator | ZION | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 60.43 | 51.98 |
| Support Level | $59.01 | $67.95 |
| Resistance Level | $59.66 | $69.48 |
| Average True Range (ATR) | 1.06 | 1.59 |
| MACD | -0.23 | 0.47 |
| Stochastic Oscillator | 20.37 | 74.62 |
Price Performance
Historical ComparisonAbout ZION Zions Bancorporation N.A.
Zions Bancorporation is a regional US bank with core operations that span 11 states. The bank is headquartered in Salt Lake City and does business primarily in the Western and Southwestern United States. Zions focuses primarily on providing banking services to small and midsize businesses, with the bulk of its loans focused on commercial and commercial real estate lending.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.